Allogene Revenue Per Share vs Current Deferred Revenue Analysis

ALLO Stock

USD 2.14 0.03 1.38%

Allogene Therapeutics financial indicator trend analysis is way more than just evaluating Allogene Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Allogene Therapeutics is a good investment. Please check the relationship between Allogene Therapeutics Revenue Per Share and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.

Revenue Per Share vs Current Deferred Revenue

Revenue Per Share vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Allogene Therapeutics Revenue Per Share account and Current Deferred Revenue. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Allogene Therapeutics' Revenue Per Share and Current Deferred Revenue is 0.86. Overlapping area represents the amount of variation of Revenue Per Share that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Allogene Therapeutics, assuming nothing else is changed. The correlation between historical values of Allogene Therapeutics' Revenue Per Share and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Revenue Per Share of Allogene Therapeutics are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Revenue Per Share i.e., Allogene Therapeutics' Revenue Per Share and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.86

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Allogene Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Allogene Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.At this time, Allogene Therapeutics' Sales General And Administrative To Revenue is very stable compared to the past year. As of the 25th of February 2025, Enterprise Value is likely to grow to about 1.2 B, while Selling General Administrative is likely to drop about 61.1 M.

	2022	2023	2024	2025 (projected)
Interest Income	4.6M	14.8M	13.3M	7.1M
Net Interest Income	4.6M	14.8M	17.0M	9.2M

Interest Income Net Interest Income

Allogene Therapeutics fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Net Invested Capital	Net Working Capital	Common Stock	Short Long Term Debt Total	Other Liab	Property Plant And Equipment Net	Net Debt	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Retained Earnings Total Equity	Capital Surpluse	Capital Lease Obligations	Inventory	Other Current Assets	Property Plant And Equipment Gross
Other Current Liab		0.97	0.97	0.98	-0.81	0.95	0.31	0.91	0.97	0.97	0.97	0.92	0.75	-0.85	0.92	0.31	0.55	-0.31	-0.08	0.02	-0.87	0.86	0.75	0.8	0.81	0.83
Total Current Liabilities	0.97		0.95	0.95	-0.72	0.88	0.25	0.83	0.92	0.95	0.96	0.84	0.64	-0.79	0.85	0.18	0.73	-0.27	0.08	-0.03	-0.78	0.8	0.64	0.65	0.75	0.78
Total Stockholder Equity	0.97	0.95		0.99	-0.71	0.93	0.1	0.8	0.92	1.0	0.97	0.89	0.61	-0.73	0.81	0.21	0.56	-0.28	0.03	0.09	-0.76	0.75	0.61	0.71	0.73	0.7
Net Tangible Assets	0.98	0.95	0.99		-0.77	0.96	0.19	0.86	0.95	0.99	0.98	0.94	0.69	-0.79	0.85	0.31	0.54	-0.32	-0.07	0.0	-0.81	0.8	0.68	0.75	0.76	0.77
Retained Earnings	-0.81	-0.72	-0.71	-0.77		-0.87	-0.62	-0.94	-0.9	-0.71	-0.75	-0.91	-0.96	0.97	-0.93	-0.77	-0.18	0.54	0.56	0.24	0.96	-0.92	-0.96	-0.88	-0.78	-0.95
Common Stock Total Equity	0.95	0.88	0.93	0.96	-0.87		0.3	0.92	0.98	0.93	0.95	0.99	0.82	-0.86	0.89	0.48	0.36	-0.34	-0.31	-0.12	-0.86	0.86	0.82	0.84	0.83	0.85
Common Stock Shares Outstanding	0.31	0.25	0.1	0.19	-0.62	0.3		0.64	0.42	0.1	0.16	0.37	0.72	-0.63	0.64	0.54	0.09	-0.29	-0.44	-0.2	-0.64	0.7	0.71	0.55	0.46	0.69
Other Stockholder Equity	0.91	0.83	0.8	0.86	-0.94	0.92	0.64		0.96	0.8	0.84	0.94	0.94	-0.95	0.98	0.57	0.38	-0.36	-0.38	-0.14	-0.96	0.98	0.93	0.89	0.84	0.97
Total Liab	0.97	0.92	0.92	0.95	-0.9	0.98	0.42	0.96		0.92	0.94	0.97	0.87	-0.92	0.95	0.48	0.45	-0.35	-0.28	-0.13	-0.91	0.92	0.87	0.84	0.85	0.92
Net Invested Capital	0.97	0.95	1.0	0.99	-0.71	0.93	0.1	0.8	0.92		0.97	0.89	0.61	-0.73	0.81	0.21	0.56	-0.28	0.03	0.09	-0.76	0.75	0.61	0.71	0.73	0.7
Net Working Capital	0.97	0.96	0.97	0.98	-0.75	0.95	0.16	0.84	0.94	0.97		0.92	0.67	-0.8	0.82	0.31	0.58	-0.32	-0.09	-0.14	-0.76	0.76	0.67	0.72	0.83	0.76
Common Stock	0.92	0.84	0.89	0.94	-0.91	0.99	0.37	0.94	0.97	0.89	0.92		0.87	-0.89	0.9	0.58	0.32	-0.4	-0.4	-0.2	-0.87	0.88	0.86	0.85	0.83	0.89
Short Long Term Debt Total	0.75	0.64	0.61	0.69	-0.96	0.82	0.72	0.94	0.87	0.61	0.67	0.87		-0.94	0.92	0.75	0.11	-0.44	-0.63	-0.26	-0.92	0.93	1.0	0.86	0.77	0.97
Other Liab	-0.85	-0.79	-0.73	-0.79	0.97	-0.86	-0.63	-0.95	-0.92	-0.73	-0.8	-0.89	-0.94		-0.95	-0.71	-0.31	0.55	0.49	0.3	0.95	-0.91	-0.94	-0.86	-0.87	-0.96
Property Plant And Equipment Net	0.92	0.85	0.81	0.85	-0.93	0.89	0.64	0.98	0.95	0.81	0.82	0.9	0.92	-0.95		0.52	0.37	-0.4	-0.32	-0.03	-0.98	0.97	0.92	0.89	0.82	0.96
Net Debt	0.31	0.18	0.21	0.31	-0.77	0.48	0.54	0.57	0.48	0.21	0.31	0.58	0.75	-0.71	0.52		-0.29	-0.7	-0.9	-0.56	-0.6	0.53	0.74	0.62	0.55	0.63
Other Assets	0.55	0.73	0.56	0.54	-0.18	0.36	0.09	0.38	0.45	0.56	0.58	0.32	0.11	-0.31	0.37	-0.29		0.03	0.57	-0.07	-0.27	0.38	0.11	0.04	0.32	0.34
Long Term Debt	-0.31	-0.27	-0.28	-0.32	0.54	-0.34	-0.29	-0.36	-0.35	-0.28	-0.32	-0.4	-0.44	0.55	-0.4	-0.7	0.03		0.44	0.31	0.45	-0.37	-0.43	-0.4	-0.4	-0.4
Cash And Short Term Investments	-0.08	0.08	0.03	-0.07	0.56	-0.31	-0.44	-0.38	-0.28	0.03	-0.09	-0.4	-0.63	0.49	-0.32	-0.9	0.57	0.44		0.55	0.38	-0.32	-0.63	-0.51	-0.44	-0.45
Net Receivables	0.02	-0.03	0.09	0.0	0.24	-0.12	-0.2	-0.14	-0.13	0.09	-0.14	-0.2	-0.26	0.3	-0.03	-0.56	-0.07	0.31	0.55		0.01	-0.08	-0.25	0.01	-0.36	-0.26
Retained Earnings Total Equity	-0.87	-0.78	-0.76	-0.81	0.96	-0.86	-0.64	-0.96	-0.91	-0.76	-0.76	-0.87	-0.92	0.95	-0.98	-0.6	-0.27	0.45	0.38	0.01		-0.95	-0.92	-0.9	-0.76	-0.94
Capital Surpluse	0.86	0.8	0.75	0.8	-0.92	0.86	0.7	0.98	0.92	0.75	0.76	0.88	0.93	-0.91	0.97	0.53	0.38	-0.37	-0.32	-0.08	-0.95		0.93	0.81	0.72	0.97
Capital Lease Obligations	0.75	0.64	0.61	0.68	-0.96	0.82	0.71	0.93	0.87	0.61	0.67	0.86	1.0	-0.94	0.92	0.74	0.11	-0.43	-0.63	-0.25	-0.92	0.93		0.86	0.77	0.97
Inventory	0.8	0.65	0.71	0.75	-0.88	0.84	0.55	0.89	0.84	0.71	0.72	0.85	0.86	-0.86	0.89	0.62	0.04	-0.4	-0.51	0.01	-0.9	0.81	0.86		0.85	0.81
Other Current Assets	0.81	0.75	0.73	0.76	-0.78	0.83	0.46	0.84	0.85	0.73	0.83	0.83	0.77	-0.87	0.82	0.55	0.32	-0.4	-0.44	-0.36	-0.76	0.72	0.77	0.85		0.79
Property Plant And Equipment Gross	0.83	0.78	0.7	0.77	-0.95	0.85	0.69	0.97	0.92	0.7	0.76	0.89	0.97	-0.96	0.96	0.63	0.34	-0.4	-0.45	-0.26	-0.94	0.97	0.97	0.81	0.79

Click cells to compare fundamentals

Allogene Therapeutics Account Relationship Matchups

Allogene Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.2B	1.0B	817.1M	642.8M	739.3M	820.0M
Other Current Liab	42.0M	34.7M	33.7M	24.3M	28.0M	27.6M
Total Current Liabilities	94.3M	48.2M	54.5M	37.1M	42.6M	46.6M
Total Stockholder Equity	1.1B	916.4M	665.9M	512.2M	589.1M	708.1M
Net Tangible Assets	628.9M	1.1B	916.4M	665.9M	765.8M	732.1M
Retained Earnings	(646.3M)	(903.3M)	(1.2B)	(1.6B)	(1.4B)	(1.3B)
Accounts Payable	10.4M	10.3M	13.9M	5.9M	6.8M	9.7M
Cash	1.0B	809.5M	576.5M	83.2M	95.6M	90.8M
Non Current Assets Total	382.7M	229.2M	288.3M	183.7M	211.3M	245.6M
Non Currrent Assets Other	14.6M	(322.1M)	32.7M	16.9M	15.2M	16.0M
Common Stock Total Equity	121K	124K	140K	142K	163.3K	121.7K
Common Stock Shares Outstanding	120.4M	135.8M	143.1M	156.9M	180.5M	125.7M
Short Term Investments	644.6M	284.0M	455.4M	365.5M	420.4M	388.4M
Non Current Liabilities Total	53.9M	74.1M	96.7M	93.5M	107.6M	65.2M
Other Stockholder Equity	1.7B	1.8B	1.9B	2.1B	2.4B	1.4B
Total Liab	148.2M	122.2M	151.2M	130.6M	150.2M	111.8M
Net Invested Capital	1.1B	916.4M	665.9M	512.2M	589.1M	708.1M
Long Term Investments	204.2M	352.2M	72.0M	3.6M	3.3M	3.1M
Total Current Assets	845.1M	809.5M	528.8M	459.1M	528.0M	574.4M
Net Working Capital	750.8M	423.1M	474.3M	422.0M	485.3M	474.6M
Common Stock	140K	142K	144K	169K	194.4K	136.1K
Short Long Term Debt Total	53.8M	69.9M	95.1M	95.1M	109.4M	73.3M
Other Liab	4.4M	3.1M	4.1M	1.6M	1.4M	1.3M
Property Plant And Equipment Net	160.1M	181.0M	196.4M	163.2M	187.7M	154.6M
Net Debt	(978.3M)	(739.6M)	(481.3M)	12.0M	13.8M	14.4M
Other Assets	8.9M	263.9M	16.1M	16.9M	19.4M	18.4M
Cash And Short Term Investments	1.0B	809.5M	576.5M	448.7M	403.8M	556.9M
Net Receivables	2.8M	6M	3.3M	1.7M	1.5M	2.6M
Liabilities And Stockholders Equity	1.2B	1.0B	817.1M	642.8M	578.6M	695.7M
Capital Lease Obligations	53.8M	69.9M	101.1M	95.1M	109.4M	74.4M
Inventory	(60.7M)	(207.0M)	(20.0M)	(62.5M)	(71.8M)	(75.4M)
Other Current Assets	10.6M	8.0M	11.5M	10.4M	12.0M	11.0M
Property Plant And Equipment Gross	160.1M	123.0M	233.3M	214.3M	246.4M	145.9M
Accumulated Other Comprehensive Income	268K	(2.6M)	(9.9M)	(955K)	(859.5K)	(902.5K)
Capital Stock	140K	142K	144K	169K	194.4K	154K
Non Current Liabilities Other	53.9M	74.1M	1.6M	5.2M	6.0M	5.7M
Property Plant Equipment	100.9M	118.8M	123.0M	196.4M	225.9M	127.8M

When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock:

How To Invest In Allogene

Details

Is Allogene Stock a good investment?

Details

What is Allogene Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.

You can also try the Stocks Directory module to find actively traded stocks across global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.55)

Quarterly Revenue Growth

(0.27)

Return On Assets

(0.26)

Return On Equity

(0.54)

The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Allogene Revenue Per Share vs Current Deferred Revenue Analysis

Revenue Per Share vs Current Deferred Revenue

Revenue Per Share vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Revenue Per Share

Current Deferred Revenue

Allogene Therapeutics fundamental ratios Correlations

Allogene Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Allogene Therapeutics fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Net Invested Capital	+ 0.99	Net Tangible Assets
Common Stock	+ 0.99	Common Stock Total Equity
Net Tangible Assets	+ 0.98	Other Current Liab

Retained Earnings Total Equity	- 0.98	Property Plant And Equipment Net
Property Plant And Equipment Gross	- 0.96	Other Liab
Retained Earnings Total Equity	- 0.96	Other Stockholder Equity
Capital Lease Obligations	- 0.96	Retained Earnings
Short Long Term Debt Total	- 0.96	Retained Earnings
Capital Surpluse	- 0.95	Retained Earnings Total Equity